Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Ophthalmology

Understanding Diabetic Retinopathy

At a Glance

Diabetic retinopathy can damage retinal blood vessels for years without noticeable vision changes. Regular comprehensive eye exams—starting at diagnosis for type 2 diabetes and generally five years after type 1 diagnosis—help detect changes early, when treatment can protect sight.

Receiving a diagnosis of diabetic retinopathy can feel like a weight on your shoulders, especially when your vision currently seems perfectly fine. It is common to feel a mix of anxiety and confusion when told that a “silent” process is occurring inside your eyes. Understanding the biology of this condition is not just about learning medical facts; it is about reclaiming a sense of control over your health by understanding exactly what your care team is monitoring [1].

How High Blood Sugar Impacts the Eye

The retina is a thin layer of light-sensitive tissue at the back of your eye that functions much like the sensor in a digital camera. To work correctly, it requires a constant, steady supply of oxygen and nutrients through a vast network of tiny blood vessels.

When blood sugar levels remain high over time (hyperglycemia), it causes metabolic and oxidative stress that damages the “neurovascular unit”—a complex team of nerve cells and blood vessels [2]. This damage often begins with the loss of pericytes, specialized cells that wrap around and support the walls of your tiny blood vessels. As these support cells disappear, the vessel walls weaken and the blood-retinal barrier—the protective seal that keeps fluid from leaking out of the blood into the eye tissue—begins to break down [3][4].

The Silent Progression (NPDR)

In its early stages, called non-proliferative diabetic retinopathy (NPDR), the damage is often microscopic. You may have tiny bulges in the vessel walls (microaneurysms) or small amounts of leakage, but because these changes often happen away from the center of your vision (the macula), you likely won’t notice any difference in how you see [5].

This “silent” nature is why screening is so vital. Research shows that a significant percentage of people living with diabetes have some form of retinopathy, yet many are unaware of it until it reaches a more advanced stage [6]. For those with Type 2 diabetes, early signs of retinopathy can sometimes be present at the very moment they are diagnosed [7].

Ischemia and the Role of VEGF

As the disease progresses, some of the tiny blood vessels in the retina may close off entirely, a process called ischemia [8]. When areas of the retina are deprived of blood and oxygen, the eye sends out a “distress signal” in the form of a protein called VEGF (Vascular Endothelial Growth Factor) [9].

While the body intends for VEGF to help, in the eye it causes two major problems:

  1. Increased Leakage: It makes existing blood vessels even more “leaky,” which can lead to swelling in the center of the vision (Diabetic Macular Edema or DME) [9].
  2. Abnormal New Growth: In later stages, called proliferative diabetic retinopathy (PDR), high levels of VEGF trigger the growth of brand-new blood vessels (neovascularization) [9][10].

These new vessels are fragile, poorly formed, and prone to bleeding into the eye, which can lead to sudden vision changes or scarring [11].

The Importance of Regular Screening

Because you cannot feel or see the early stages of retinopathy, regular comprehensive eye exams are the only way to catch the disease before it threatens your sight. Current evidence suggests that for Type 1 diabetes, regular screenings should generally begin 5 years after diagnosis, though age and puberty also affect the timing [12]. For Type 2 diabetes, screenings should begin immediately at the time of diagnosis [7].

Your doctor may adjust how often you need to be seen based on your specific risk factors, such as your HbA1c levels, blood pressure, and how long you have lived with diabetes [13][12]. Catching changes early allows your medical team to use treatments like anti-VEGF injections or laser therapy to protect your vision.

Coping with the Emotional Impact

It is completely normal to feel distressed, anxious, or even depressed when facing a vision-threatening condition [1]. The fear of losing independence or the ability to work is a significant burden. Studies have shown that the severity of retinopathy is often linked to higher levels of emotional distress [1][14].

Acknowledging these feelings is an important part of your care. Managing diabetic retinopathy is a long-term journey that involves not just your eye doctor, but also your primary care team and potentially mental health support to help you navigate the psychological challenges of chronic illness [1].

Common questions in this guide

Can diabetic retinopathy develop even if my vision seems normal?
Yes. Early damage often affects small blood vessels away from the macula, the center of the retina used for sharp vision, so you may not notice changes. Regular comprehensive eye exams can find it before it threatens sight.
When should I start eye screening if I have diabetes?
For type 1 diabetes, regular screening generally begins about five years after diagnosis, although age and puberty can change the timing. For type 2 diabetes, screening should begin when diabetes is diagnosed. Your clinician may adjust the schedule based on your health and eye findings.
How do my HbA1c and blood pressure affect diabetic retinopathy?
Higher HbA1c levels and high blood pressure can increase the risk that diabetic retinopathy will develop or worsen, especially when diabetes has been present for a long time. Your care team uses these factors, along with your eye findings, to decide how closely to monitor you.
What happens when diabetic retinopathy progresses to the proliferative stage?
Some retinal blood vessels close, depriving areas of oxygen. The eye releases VEGF, which can cause fragile new blood vessels to grow; these vessels may bleed or form scar tissue and cause sudden vision changes. This stage may require treatments such as anti-VEGF injections or laser therapy.
What treatments may be used if there is leakage or abnormal blood vessel growth?
Anti-VEGF injections can reduce the effects of VEGF, including leakage and abnormal vessel growth. Laser therapy may also be used to help protect vision. The appropriate treatment depends on the stage of retinopathy and findings in each eye.
Is it normal to feel anxious or depressed about diabetic retinopathy?
Yes. Fear about vision, independence, or work can cause distress, anxiety, or depression when living with a vision-threatening condition. Tell your primary care or eye care team how you are feeling so they can help connect you with support, including mental health care when needed.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my recent eye exam, what stage of retinopathy do I have in each eye?
  2. 2.How do my current HbA1c and blood pressure levels affect the risk of my retinopathy progressing?
  3. 3.How often should I have an eye exam, and what specific changes should I watch for between visits?
  4. 4.If my vision is currently clear, why is it still important to monitor my retina so closely?
  5. 5.What are the next steps if you see signs of leakage or new vessel growth in my next exam?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    The relationship between diabetic retinopathy and psychosocial functioning: a systematic review.

    Khoo K, Man REK, Rees G, et al.

    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2019; (28(8)):2017-2039 doi:10.1007/s11136-019-02165-1.

    PMID: 30879245
  2. 2

    Dysfunction of the Neurovascular Unit in Diabetic Retinopathy: Advances from Molecular Mechanisms to Targeted Interventions.

    Zhao C, Qin L, Zhang J, Wang X

    Stem cell reviews and reports 2026; doi:10.1007/s12015-026-11213-6.

    PMID: 42622757
  3. 3

    Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets.

    Das A, McGuire PG, Rangasamy S

    Ophthalmology 2015; (122(7)):1375-94.

    PMID: 25935789
  4. 4

    Plastic roles of pericytes in the blood-retinal barrier.

    Park DY, Lee J, Kim J, et al.

    Nature communications 2017; (8()):15296 doi:10.1038/ncomms15296.

    PMID: 28508859
  5. 5

    The unmet need for better risk stratification of non-proliferative diabetic retinopathy.

    Sivaprasad S, Pearce E

    Diabetic medicine : a journal of the British Diabetic Association 2019; (36(4)):424-433 doi:10.1111/dme.13868.

    PMID: 30474144
  6. 6

    IDF Diabetes Atlas: A review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018.

    Thomas RL, Halim S, Gurudas S, et al.

    Diabetes research and clinical practice 2019; (157()):107840 doi:10.1016/j.diabres.2019.107840.

    PMID: 31733978
  7. 7

    Oxidative Stress and Microvascular Alterations in Diabetic Retinopathy: Future Therapies.

    Rodríguez ML, Pérez S, Mena-Mollá S, et al.

    Oxidative medicine and cellular longevity 2019; (2019()):4940825 doi:10.1155/2019/4940825.

    PMID: 31814880
  8. 8

    The Role of Inflammation in Diabetic Retinopathy.

    Forrester JV, Kuffova L, Delibegovic M

    Frontiers in immunology 2020; (11()):583687 doi:10.3389/fimmu.2020.583687.

    PMID: 33240272
  9. 9

    Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease: From Bench to Bedside.

    Campochiaro PA, Aiello LP, Rosenfeld PJ

    Ophthalmology 2016; (123(10S)):S78-S88 doi:10.1016/j.ophtha.2016.04.056.

    PMID: 27664289
  10. 10

    Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy.

    Babapoor-Farrokhran S, Jee K, Puchner B, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2015; (112(23)):E3030-9 doi:10.1073/pnas.1423765112.

    PMID: 26039997
  11. 11

    Epidemiology of Treated Diabetes Ocular Complications in France 2008-2018-The LANDSCAPE French Nationwide Study.

    Creuzot-Garcher C, Massin P, Srour M, et al.

    Pharmaceutics 2022; (14(11)) doi:10.3390/pharmaceutics14112330.

    PMID: 36365148
  12. 12

    Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes.

    , Nathan DM, Bebu I, et al.

    The New England journal of medicine 2017; (376(16)):1507-1516 doi:10.1056/NEJMoa1612836.

    PMID: 28423305
  13. 13

    Evidence-based Danish guidelines for screening of diabetic retinopathy.

    Grauslund J, Andersen N, Andresen J, et al.

    Acta ophthalmologica 2018; (96(8)):763-769 doi:10.1111/aos.13936.

    PMID: 30311394
  14. 14

    Social determinants of diabetic retinopathy and impact of sight-threatening diabetic retinopathy: A study from Pune, India.

    Kulkarni S, Patil V, Kashikar R, et al.

    Indian journal of ophthalmology 2023; (71(2)):358-362 doi:10.4103/ijo.IJO_1660_22.

    PMID: 36727320

This page is for informational purposes only and does not constitute medical advice. It explains diabetic retinopathy screening and progression; your eye doctor and diabetes care team can interpret your results and recommend care for your situation.

Get notified when new evidence is published on diabetic retinopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.